[Angiogenesis: all a radiation oncologist should know].
Angiogenesis is a crucial requirement for tumorogenesis, providing oxygen and nutrient supply necessary for tumor growth and metastasis. This is a complex phenomenon regulated by many factors that can now be targeted by novel anti-cancer therapies. Antiangiogenic approaches have shown positive results in clinical trials and are now approved as standard of care in medical oncology. Many clinical trials are evaluating antiangiogenic agents in association with radiotherapy. This review aims to summarize the knowledge useful to the understanding of these novel therapies and their potential in combination with radiotherapy.
Mazeron
R
R
UPRES EA2710, Laboratoire de Radiosensibilité des Tumeurs et des Tissus Sains, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, Villejuif, France.
Bourhis
J
J
Deutsch
E
E
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006801:Humans; D006931:Hyperbaric Oxygenation; D009369:Neoplasms / Q000098:blood supply* / Q000378:metabolism / Q000628:therapy*; D009389:Neovascularization, Pathologic; D011838:Radiation-Sensitizing Agents; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D011838:Radiation-Sensitizing Agents; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors